Skip to main content
TScan Therapeutics, Inc. logo

TScan Therapeutics, Inc. — Investor Relations & Filings

Ticker · TCRX ISIN · US89854M1018 US Professional, scientific and technical activities
Open in API
Filings indexed 310 across all filing types
Latest filing 2023-02-03 Major Shareholding Noti…
Country US United States of America
Listing US TCRX

About TScan Therapeutics, Inc.

https://www.tscan.com

TScan Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of cancer. The company's approach is centered on discovering highly effective, naturally occurring TCRs and using them to genetically reprogram T cells. This strategy aims to harness the power of the human immune system to deliver safe and effective immunotherapies to patients.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2023
Major Shareholding Notification
2023-02-03 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is used for current reports to announce major events. The content describes a press release about FDA clearance of investigational new drug applications and plans for clinical trials. There are no financial statements or detailed financial data presented. The document length is 3956 characters, which is relatively short and mainly announces an event rather than providing a full report. It includes a press release as an exhibit. This fits the profile of a Regulatory Filing (RNS) as it is a general regulatory announcement and does not fit into more specific categories like earnings release or capital update.
2023-01-23 English
FORM 4 SUBMISSION
Director's Dealing
2022-12-29 English
Regulatory Filings 2022
Regulatory Filings
2022-11-15 English
Regulatory Filings 2022
Regulatory Filings
2022-11-15 English
S-3
Capital/Financing Update Classification · 100% confidence The document is a Form S-3 Registration Statement filed with the SEC by TScan Therapeutics, Inc. It is a registration statement under the Securities Act of 1933, used for registering securities for sale to the public. The text includes details about the securities being registered, the selling stockholders, and the terms of the offering. It is not a financial report, earnings release, or management discussion. It is a capital markets filing related to fundraising and securities offering. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it is the actual registration statement, not just an announcement of a report.
2022-11-09 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.